Malin Corporation PLC
Malin Corporation PLC is a pharmaceutical company focused on the development and commercialization of medical devices and specialty pharmaceutical products, primarily in the areas of pain management and urology.
Business. Malin Corporation PLC (MLCM.I) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding the company's operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the business is described at the industry level without geographic or segmental breakdowns.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Malin Corporation PLC (MLCM.I) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding the company's operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the business is described at the industry level without geographic or segmental breakdowns.
Malin Corporation PLC has a fully diluted share count of 4,326,168, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is not available, limiting the ability to assess its relative value compared to industry peers.
The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against the preferred metrics for the Pharmaceuticals industry, such as EBITDA margin or ROIC. Without these metrics, it is not possible to determine whether Malin Corporation PLC is outperforming or underperforming the industry median.
Malin Corporation PLC's revenue concentration by segment and geography is not disclosed in the available data, which limits the ability to assess the company's exposure to specific markets or product lines. This lack of transparency could pose a risk to investors seeking to understand the company's diversification and resilience to regional or product-specific shocks.
The company's growth trajectory is not quantified in the current dataset, as no outlook data is available for the current or next fiscal year. Analysts have provided a mean price target of 15.50 EUR, with a median and high target also at 15.50 EUR, and a mean recommendation of 2.00 (indicating a "Buy" rating). However, the absence of revenue history and growth projections makes it difficult to assess the company's long-term potential.
The company's risk profile is characterized by low dilution risk and an inability to assess liquidity risk due to missing balance-sheet data. No recent events, such as filings or transcripts, are available to provide additional context on the company's strategic direction or operational performance.
No recent events, such as earnings calls, regulatory filings, or press releases, are available in the current dataset to provide insight into the company's recent performance or strategic initiatives.
- Malin Corporation PLC has no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities.
- Analysts have assigned a "Buy" rating to Malin Corporation PLC, with a mean price target of 15.50 EUR.
- The company's profitability and return metrics are not available, making it difficult to assess its performance against industry peers.
- Revenue concentration by segment and geography is not disclosed, limiting the ability to assess the company's diversification and resilience.
- The company's growth trajectory is not quantified in the current dataset, and no outlook data is available for the current or next fiscal year.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -€5.7M.
- ▍Operating income -€5.7M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Malin Corporation PLC Market data — financials · 2026-05-28
- Malin Corporation PLC Market data — analyst estimates · 2026-05-28